Liquid biopsies have emerged as a powerful tool in precision oncology, offering advantages over traditional tissue biopsies such as reduced invasiveness and the ability to provide real-time molecular insights. These biopsies primarily involve the isolation of circulating extracellular nucleic acids (cfDNA and ctDNA) and circulating tumor cells (CTCs) from blood. The clinical applications of liquid biopsies are diverse, including cancer screening, early detection, prognostication, identification of actionable alterations, monitoring of response and resistance to therapy, and assessment of tumor heterogeneity. Liquid biopsies can also aid in personalized therapy, particularly in cases where tissue biopsies are not feasible. Despite their promising potential, the clinical utility of liquid biopsies remains to be fully validated, and challenges such as low tumor shedding and false positives due to clonal hematopoietic mutations (CHIP) must be addressed. Ongoing research and clinical trials, including the exploration of alternate bodily fluids and the integration of artificial intelligence (AI), are expected to further advance the field of liquid biopsies.Liquid biopsies have emerged as a powerful tool in precision oncology, offering advantages over traditional tissue biopsies such as reduced invasiveness and the ability to provide real-time molecular insights. These biopsies primarily involve the isolation of circulating extracellular nucleic acids (cfDNA and ctDNA) and circulating tumor cells (CTCs) from blood. The clinical applications of liquid biopsies are diverse, including cancer screening, early detection, prognostication, identification of actionable alterations, monitoring of response and resistance to therapy, and assessment of tumor heterogeneity. Liquid biopsies can also aid in personalized therapy, particularly in cases where tissue biopsies are not feasible. Despite their promising potential, the clinical utility of liquid biopsies remains to be fully validated, and challenges such as low tumor shedding and false positives due to clonal hematopoietic mutations (CHIP) must be addressed. Ongoing research and clinical trials, including the exploration of alternate bodily fluids and the integration of artificial intelligence (AI), are expected to further advance the field of liquid biopsies.